Use of class I histone deacetylase inhibitor romidepsin in combination regimens

Abstract

Histone deacetylase (HDAC) inhibitors are epigenetic-modifying agents that have shown promise as anticancer therapies. Several HDAC inhibitors have been approved by the US Food and Drug Administration (FDA) as single-agent therapies to treat T-cell lymphoma. The synergistic combination of HDAC inhibitors with other anticancer agents has the potential to constitute treatment regimens with enhanced efficacy. Romidepsin is a structurally unique, potent, bicyclic class 1 selective HDAC inhibitor approved by the FDA for the treatment of patients with peripheral T-cell lymphoma who have had at least 1 prior therapy and patients with cutaneous T-cell lymphoma who have had at least 1 prior systemic therapy. Here, we review data that support the use of romidepsin in combination with other anticancer agents for the treatment of various malignancies. Promising results have emerged from early clinical studies, supporting the potential for romidepsin combination regimens to constitute safe and effective treatments for cancer.

Keywords:

• Combination therapy
• epigenetics
• histone deacetylase inhibitor

Acknowledgements

The authors take full responsibility for the content of this manuscript, but thank Stacey Rose, PhD, and William Ho, PhD (MediTech Media), for providing medical editorial assistance. Financial support for medical editorial assistance was provided by Celgene Corporation.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article at http: http://dx.doi.org/10.3109/10428194.2016.1160082.